A new clinical trial update was posted on August 11, 2026 for ecnoglutide, listed under the identifier NCT07628127. The trial is titled "A Trial of Oral VRB-103 Alone or in Combination With Oral Ecnoglutide (VRB-101) in Participants With Obesity or Overweight." It is registered as a Phase 1 study. The trial's current status is recruiting, meaning it is actively seeking participants with obesity or overweight to enroll.
The study is designed to evaluate oral VRB-103 given alone as well as in combination with oral ecnoglutide, referred to in the listing as VRB-101. As a Phase 1 trial, it represents an early stage of clinical investigation. No results, findings, or outcomes have been reported as part of this update. The listing reflects only the trial's design, phase, and recruitment status as of the date given.
Ecnoglutide remains classified as an unapproved compound under research investigation. This update does not constitute evidence of safety or effectiveness for any use. Further details on trial design, eligibility, and status can be found at the provided clinical trial registry listing. Readers interested in background on this compound can consult the compound overview for additional context.